CompletedPhase 2NCT02761057
Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed
Studying Papillary renal cell carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Sumanta K Pal, MDSWOG Cancer Research Network
- Intervention
- Biospecimen Collection(procedure)
- Enrollment
- 152 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2016 – 2023
Study locations (30)
- Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States
- Anchorage Radiation Therapy Center, Anchorage, Alaska, United States
- Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States
- Alaska Oncology and Hematology LLC, Anchorage, Alaska, United States
- Alaska Women's Cancer Care, Anchorage, Alaska, United States
- Anchorage Oncology Centre, Anchorage, Alaska, United States
- Katmai Oncology Group, Anchorage, Alaska, United States
- Providence Alaska Medical Center, Anchorage, Alaska, United States
- Kingman Regional Medical Center, Kingman, Arizona, United States
- Mercy Hospital Fort Smith, Fort Smith, Arkansas, United States
- John L McClellan Memorial Veterans Hospital, Little Rock, Arkansas, United States
- PCR Oncology, Arroyo Grande, California, United States
- Sutter Auburn Faith Hospital, Auburn, California, United States
- Sutter Cancer Centers Radiation Oncology Services-Auburn, Auburn, California, United States
- AIS Cancer Center at San Joaquin Community Hospital, Bakersfield, California, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
Canadian Cancer Trials Group
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02761057 on ClinicalTrials.govOther trials for Papillary renal cell carcinoma
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE2NCT05411081Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 TrialNational Cancer Institute (NCI)
- RECRUITINGPHASE2NCT05096390Axitinib +/- Pembrolizumab in First Line Treatment of mPRCCCentre Leon Berard
- ACTIVE NOT RECRUITINGPHASE3NCT05043090Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCCAstraZeneca